YOLFTbeta
Prelude Therapeutics Inc

Prelude Therapeutics Inc

PRLD · NASDAQ · Healthcare / Biotechnology

3.45USD-0.07 (-1.99%)

Price History

Full chart

Market Stats

Previous Close3.52
Open3.53
Day Range3.27 – 3.53
52-Week Range1.15 – 6.83
Volume262.09K
Market Cap312.03M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.73
Dividend Yield0.00%
Beta0.96
50-Day Avg5.00
200-Day Avg3.84

About

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Krishna Vaddi D.V.M., Ph.D.
  • Employees79
  • Headquarters175 Innovation Boulevard, Wilmington, DE, United States, 19805, USA
  • Websitehttps://preludetx.com

Leadership

  • Dr. Krishna Vaddi D.V.M., Ph.D.Founder, CEO & Director · b. 1966
  • Mr. Bryant David Lim J.D.CFO, Chief Legal Officer & Corporate Secretary · b. 1971
  • Dr. Peggy A. Scherle Ph.D.Chief Scientific Officer · b. 1962
  • Ms. Aimee Crombie Ph.D.Senior VP and Head of Strategic Planning & Operations
  • Dr. Madhu Pudipeddi Ph.D.Senior Vice President of Technical Operations
  • Mr. Robert A. Doody Jr.Senior Vice President of Investor Relations
  • Ms. Michele Porreca M.B.A.Chief People Officer
  • Dr. Andrew P. Combs Ph.D.Executive VP & Chief Chemistry Officer · b. 1967
  • Mr. Naveen Babbar Ph.D.Senior Vice President of Translation Medicine
  • Dr. Wan-Jen Hong M.D.Senior Vice President of Clinical Development · b. 1979

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0000007.00M12.14M
Growth (%)-------+73.43%
Cost of Revenue149.00K382.00K542.00K2.24M3.04M1.17M1.77M1.71M
Gross Profit-149.00K-382.00K-542.00K-2.24M-3.04M-1.17M7.00M10.43M
Gross Margin------100.00%85.91%
Operating Expense14.83M27.73M58.22M111.49M120.50M131.11M146.71M115.00M
Operating Income-14.97M-28.11M-58.76M-113.73M-123.54M-132.28M-139.71M-104.57M
Operating Margin-------1995.91%-861.33%
EBITDA-14.83M-27.73M-58.22M-112.82M-122.22M-120.66M-125.40M-97.79M
EBITDA Margin-------1791.44%-805.49%
Net Income-14.68M-27.57M-56.93M-110.78M-107.34M-121.83M-127.17M-99.50M
Net Income Margin-------1816.76%-819.59%
R&D12.62M24.28M48.18M86.78M92.89M103.39M118.00M94.30M
R&D as % of Total Revenue------1685.64%776.77%
Interest Expense0002.04M1.32M---

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets16.41M21.87M223.59M305.10M220.50M277.67M175.51M141.31M
Total Liabilities39.10M71.28M11.41M19.20M25.06M40.58M44.06M72.68M
Total Equity-22.69M-49.41M212.18M285.90M195.44M237.09M131.46M68.64M
Cash15.60M18.88M218.31M31.83M30.61M25.29M12.47M35.26M
Total Debt-258.00K-1.74M1.83M16.89M18.02M17.79M
Net Debt-15.60M-18.62M-218.31M-30.09M-28.77M-8.40M5.55M-17.47M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-12.95M-25.66M-46.18M-83.53M-83.73M-107.06M-102.89M-56.30M
Investing Cash Flow-529.00K-780.00K-621.00K-263.80M81.69M-34.65M90.19M53.46M
Financing Cash Flow17.94M29.73M246.23M164.90M815.00K136.40M-120.00K24.82M
Capital Expenditure529.00K780.00K621.00K2.32M3.02M3.51M764.00K67.00K
Free Cash Flow-13.48M-26.45M-46.80M-85.85M-86.75M-110.58M-103.65M-56.37M
FCF to OCF104.08%103.04%101.34%102.78%103.61%103.28%100.74%100.12%

Earnings

Report DateSep 25, 2020Nov 10, 2020Mar 16, 2021May 11, 2021Aug 12, 2021Nov 12, 2021Mar 16, 2022May 10, 2022Aug 9, 2022Nov 14, 2022Mar 15, 2023May 8, 2023Aug 3, 2023Nov 1, 2023Feb 15, 2024May 7, 2024Aug 12, 2024Nov 6, 2024Feb 13, 2025May 6, 2025Aug 14, 2025Nov 12, 2025Mar 18, 2026May 12, 2026Aug 11, 2026Nov 11, 2026
EPS Estimate-0.39-0.34-0.47-0.42-0.49-0.62-0.68-0.65-0.63-0.64-0.63-0.70-0.63-0.58-0.49-0.48-0.43-0.46-0.47-0.46-0.43-0.35-0.13-0.27-0.17-0.16
EPS Actual-5.50-0.38-0.45-0.47-0.58-0.66-0.71-0.63-0.58-0.63-0.60-0.58-0.54-0.45-0.45-0.42-0.46-0.43-0.37-0.42-0.41-0.26-0.20-0.13-0.14-
Surprise-1310.26%-11.76%4.26%-11.90%-18.37%-6.45%-4.41%3.08%7.94%1.56%4.76%17.14%14.29%22.41%8.16%12.50%-6.98%6.52%20.82%8.70%4.65%25.71%-53.85%51.85%17.65%-
TimingAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap312.03M
Enterprise Value209.45M
Trailing P/E0.00
Forward P/E0.00
Price / Sales13.89
Price / Book2.57
EPS-0.73
Book Value1.30
Revenue (TTM)22.42M
Gross Profit (TTM)22.42M
EBITDA-64.51M
Profit Margin-269.75%
Operating Margin-270.93%
Return on Equity-57.73%
Return on Assets-27.15%
Shares Outstanding65.08M
Shares Float22.07M
Beta0.96
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 4 analystsTarget 9.20
  • Strong Buy
    1
  • Buy
    2
  • Sell
    1

Ownership Breakdown

Institutions
76.46%
Insiders
13.76%
Retail / Other
9.78%

Top Institutional Holders

  • Orbimed Advisors LLC
    10.91M13.67%
  • Baker Bros Advisors LP
    10.12M12.69%
  • Soleus Capital Management, L.P.
    3.38M4.23%
  • Kynam Capital Management, LP
    2.42M3.03%
  • Vanguard Capital Management, LLC
    1.23M1.54%
  • Two Sigma Investments LLC
    993.37K1.24%
  • Millennium Management LLC
    844.99K1.06%
  • Adage Capital Partners Gp LLC
    766.10K0.96%
  • Sphera Funds Management Ltd.
    558.34K0.70%
  • Acadian Asset Management LLC
    511.52K0.64%
  • Marshall Wace Asset Management Ltd
    358.91K0.45%
  • Morgan Stanley - Brokerage Accounts
    322.16K0.40%
  • BlackRock Inc
    321.89K0.40%
  • Geode Capital Management, LLC
    302.46K0.38%
  • Renaissance Technologies Corp
    275.20K0.34%
  • Susquehanna International Group, LLP
    267.79K0.34%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.51M1.90%
  • iShares Russell 2000 ETF
    648.11K0.81%
  • Biotech Growth Ord
    346.50K0.43%
  • Fidelity Small Cap Index
    301.34K0.38%